Checkpoint begins Phase I of anti-PD-L1 mAb in cancer

In October, Checkpoint Therapeutics Inc. (NASDAQ:CKPT) began a Phase I trial of CK-301 to treat about 80 checkpoint therapy-naïve

Read the full 194 word article

User Sign In